Table 3.
Patient outcomes, n = 139.
| All DLI n = 139 |
Classical DLI n = 68 (48.9%) |
gDLI n = 71 (51.1%) |
p | |
|---|---|---|---|---|
| Complete response, n (%), n = 131 | n = 64 | n = 67 | 0.28 | |
| Yes | 50 (38.2) | 21 (32.8) | 29 (43.3) | |
| No | 81 (61.8) | 43 (67.2) | 38 (56.7) | |
| Post-DLI GvHD, n (%), n = 137 | n = 66 | |||
| All grades of GvHD | 64 (46.7) | 30 (45.5) | 34 (47.9) | 0.86 |
| Treatment-requiring GvHD, n (%) | 32 (23.4) | 14 (21.2) | 18 (25.4) | 0.81 |
| Chimerism, n (%), n = 127 | n = 61 | n = 66 | 0.63 | |
| 100% donor | 88 (69.3) | 43 (70.5) | 45 (68.2) | |
| Mixed | 38 (29.9) | 17 (27.9) | 21 (31.8) | |
| Recipient | 1 (0.8) | 1 (1.6) | ||
| Progression-free survival | ||||
| Median PFS (months, IQR) | 9 (3–35) | 11 (2–35) | 9 (4–33) | 0.90 |
| 5-year PFS (%, IQR) | 38 (29–48) | 36 (24–52) | 40 (29–56) | |
| Overall survival, | ||||
| Median OS (months, IQR) | 22 (6–50) | 22 (4–33) | 21 (6–47) | 0.50 |
| 5 years of OS (%, IQR) | 37 (29–47) | 37 (27–52) | 36 (26–52) | |
| Cause of Mortality, n (%), n = 82 | n = 70 | 0.14 | ||
| Progression | 65 (47.1) | 37 (54.4) | 28 (40) | |
| Toxicity | 14 (10.1) | 5 (7.4) | 9 (12.9) | |
| Other | 3 (2.2) | 0 | 3 (4.3) |
Abbreviations: gDLI = g-csf primed DLI, DLI = donor lymphocyte infusion, GvHD = graft versus host disease, IQR = interquartile range, OS = overall survival, PFS = progression-free survival.